Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

What symbol and exchange does Savara shares trade?

Savara trades on the NASDAQ stock market under the symbol SVRA.

What is Savara stock price doing today?

As of October 21, 2026, SVRA stock price climbed to $4.87 with 491,431 million shares trading.

What is Savara's Beta?

SVRA has a beta of 1.59, meaning it tends to be more sensitive to market movements. SVRA has a correlation of 0.12 to the broad based SPY ETF.

How much is Savara worth?

SVRA has a market cap of $1.00 billion. This is considered a Small Cap stock.

What is the highest and lowest price Savara traded in the last 3 year period?

In the last 3 years, SVRA traded as high as $7.01 and as low as $1.89.

What are the top ETFs holding Savara?

The top ETF exchange traded funds that SVRA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

Is Savara (SVRA) a good investment?

SVRA has outperformed the market in the last year with a price return of +18.5% while the SPY ETF gained +16.1%. However, in the short term, SVRA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -11.3% vs +4.2% return in SPY. But in the last 2 weeks, SVRA shares have fared better than the market returning +4.7% compared to SPY -1.0%.

What are the support and resistance levels for Savara (SVRA)?

SVRA support price is $4.59 and resistance is $4.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SVRA shares will trade within this expected range on the day.